FSD Pharma Inc.
520 William Street
Cobourg, ON K9A 3A5 Canada
Phone: (647) 864-7969
FSD Pharma Inc. is a publicly traded holding company since May 2018. FSD Pharma BioSciences, Inc. (a wholly-owned subsidiary) is a specialty biotech pharmaceutical research and development (R&D) company focused on developing multiple applications of its lead compound, FSD201 ultramicronized Palmitoyl ethylamine (PEA). Ultramicronized PEA is known to target the cannabinoid-2 (CB2) receptors of the end-cannabinoid system of the human body and acts by down-regulating the pro-inflammatory cytokines to effectuate an anti-inflammatory response. The Company has successfully completed a Phase 1 first-in-human safety and tolerability study for FSD201, with the compound found to be safe with no serious adverse side effects. This study also validated considerable scientific literature published in the European Union that claims safety and tolerability of micro-PEA. Ultramicronized PEA is being dispensed in Italy and Spain as a prescription-based medical food supplement since 2004. The Company received permission from the Food and Drug Administration (FDA) on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients. FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under Canada’s Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019. The Company is licensed to cultivate cannabis in approximately 25,000 square feet of its facility in Cobourg, Ontario.
* The Corporate Snapshot was last updated on July 10, 2020.